Avience Biomedicals IPO Subscription on Day 3: Retail and HNI Investors Drive Massive 132.42x Demand as Issue Closes Today

Mumbai, June 22: Avience Biomedicals IPO has witnessed a sharp surge in investor interest on the final day of bidding, with the SME issue attracting overwhelming demand across investor categories. As of 11:50 AM on June 22, the public issue was subscribed 132.42 times, making it one of the most heavily subscribed SME offerings currently in the market.

The ₹30.24 crore IPO, which opened for subscription on June 18, closes today. With only a few hours of bidding remaining, subscription levels have already moved significantly higher than those recorded during the first two days of the issue.

Avience Biomedicals IPO Subscription Crosses 132 Times on Final Day

Exchange data shows the IPO received bids for more than 12.73 crore shares against 9.61 lakh shares available for subscription, resulting in an overall subscription of 132.42 times.

The sharp jump reflects aggressive participation from retail as well as non-institutional investors, while institutional demand also strengthened considerably on the closing day.

Category-Wise Subscription Status

• QIB (Ex Anchor): 9.80x
• NII: 212.17x
• bNII: 228.17x
• sNII: 180.17x
• Retail Investors: 167.84x
• Overall Subscription: 132.42x

The issue had received more than 79,000 applications by the latest update.

Retail Investors Continue to Lead the Demand

Retail participation remained exceptionally strong throughout the subscription period.

The retail portion was subscribed 167.84 times, indicating strong interest from individual investors despite the issue already witnessing heavy demand during the earlier days of bidding.

For many SME IPOs, retail participation tends to accelerate towards the close, and Avience Biomedicals appears to be following that trend in a big way.

HNI Segment Records Explosive Response

The biggest highlight of the issue has been the response from non-institutional investors.

The NII category was subscribed 212.17 times, with the larger-ticket bNII portion booked 228.17 times and the sNII segment subscribed 180.17 times.

Such strong HNI participation has played a major role in pushing overall subscription numbers into triple digits.

Institutional Investors Join In On Closing Day

Qualified Institutional Buyers also increased their participation as the issue approached closure.

The QIB (Ex Anchor) portion was subscribed 9.80 times, a substantial improvement from earlier subscription levels. Institutional interest often emerges towards the final stages of an IPO, and Avience Biomedicals has seen a similar pattern.

Subscription Momentum Through The Bidding Period

The demand trajectory highlights how rapidly investor interest accelerated during the subscription window.

• Day 1 Overall Subscription: 10.75x
• Day 2 Overall Subscription: 43.79x
• Day 3 Overall Subscription: 132.42x

Retail subscriptions rose from 15.69 times on Day 1 to 167.84 times by Day 3, while the NII category jumped from 13.49 times to 212.17 times during the same period.

Avience Biomedicals IPO Details

Avience Biomedicals is raising ₹30.24 crore through a fresh issue of shares.

Key IPO Details

• Issue Size: ₹30.24 crore
• Fresh Issue: 14.53 lakh shares
• Price Band: ₹196 to ₹208 per share
• Issue Price: ₹208 per share
• Lot Size: 600 shares
• IPO Closes: June 22, 2026
• Tentative Allotment: June 23, 2026
• Refunds Initiation: June 24, 2026
• Shares Credit Date: June 24, 2026
• Tentative Listing Date: June 25, 2026
• Listing Platform: NSE SME

What Happens After The IPO Closes?

With bidding set to conclude today, investor attention will shift towards the allotment process.

Given the exceptionally high subscription levels, allotment in the retail and HNI categories is expected to be highly competitive. Successful applicants are expected to receive shares in their demat accounts on June 24, 2026, while refunds or mandate releases for unsuccessful bidders are scheduled for the same day.

The company is currently expected to debut on the NSE SME platform on June 25, 2026.

About Avience Biomedicals

Avience Biomedicals operates in the healthcare and biomedical segment and is focused on providing products and solutions catering to healthcare requirements. The company has launched the public issue to support its growth plans and strengthen its business operations.

Conclusion

Avience Biomedicals IPO has emerged as one of the standout SME offerings of the week, with the issue subscribed 132.42 times by Day 3. Strong participation from retail investors and HNIs, coupled with improving institutional demand, has driven subscription levels sharply higher ahead of the close. Investors will now watch the allotment process and listing schedule as the issue moves into its next phase.

Source:

• https://www.chittorgarh.net/reports/anchor-investor/aviencebiomedicals_anchorallocationreport.pdf